Finally, the first positive trial of immunotherapy in the definitive Rx of mucosal LA # HNCA; look forward to more practice changing IO studies thelancet.com/journals/lance… thelancet.com/journals/lance…

BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc NRG Oncology (h/t Yao Yu) C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Nancy Lee Henning Willers, MD, FASTRO emdgroup.com/en/news/xevina…

Published today! We found that cancer cells adapting to drug treatments don't simply switch from a sensitive to resistant state; instead there's a ‘resistance continuum’ of resistant phenotypes with epigenetically reprogrammed states. 🧵⬇️ nature.com/articles/s4158… @Gustavo_SFranca

Trends in incidence of #OralCavity #SquamousCellCarcinoma in the United States 2001-2019 Salma Ramadan Sid Puram, MD PhD (Puram Lab) R. Alex Harbison, MD MS Zaid Al-Qurayshi ow.ly/3yyo50SG4zj Flavio G Rocha, MD, FACS, FSSO Michael Cavnar Julie Hallet @SKMaithel Juliet S Lumati (Okoroh) MD MPH FACS FSSO Lee M. Ocuin MD, FACS Aradhya Nigam, MD

THIRTY-SIX POINTS 🇺🇸 #USABMNT #Paris2024 #Basketball

Merck689 (neoadjuvant pembro for HPV neg HNSCC) with a positive result! Major step forward for our field. Congrats to Ravi Uppaluri, MDPhD and Doug Adkins who pioneered this work @WUSTL_ENT and @WashUOnc before this trial. #headandneck #cancer WashU/BJC Head and Neck Tumor Center at Siteman merck.com/news/mercks-ke…

We are excited to share the first-ever positive interim data for adjuvant immunotherapy in high-risk #CSCC, a form of non-melanoma #skincancer. Read more about the Phase 3 trial results in this investigational indication.

Please join for a very interesting panel tomorrow on preclinical models in H&N cancer! Fortunate to have 3 wonderful experts - Dechen Lin (USC), Uma Duvvuri (NYU), and Antonio Jimeno (Colorado)

In an unprecedented move, research-grant reviews have been suspended indefinitely at the world’s largest public funder of biomedical research go.nature.com/4gclXG0

The latest study from Sid Puram, MD PhD (Puram Lab) WashUMedENT suggests that despite high accuracy for individual margins, IFSH has limitations in predicting final surgical margin status in HPV-related OPSCC, particularly for base of tongue primaries and deep margins. jamanetwork.com/journals/jamao…

JCI - Immunotherapeutic strategies in head and neck cancer: challenges and opportunities jci.org/articles/view/… Team effort with Drs. Liu, Sid Puram, MD PhD (Puram Lab), Peng, and Varvares to update the past, present, and future of immunotherapy in head and neck cancer.

Last week was the formal dedication of The Robert Ebert and Greg Stubblefield Head & Neck Tumor Center, named in honor of two courageous h&n cancer patients. One of the 1st of the kind in the country, we celebrate the life-saving research & care this center makes possible!

Great trip out to Dalhousie University for their OTO Resident Research Day! Wonderful presentations and good catching up with former WashUMedENT H&N fellow and DAL Chief Dr. Mark Taylor and the whole faculty group here. Looking forward to more collaboration in future!

This is insane. I think I need to channel my inner Tyrese Haliburton for my next #NIH grant submission.

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery + risk adapted adjuvant therapy. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS.ascopubs.org/doi/10.1200/JC…

Here it is! KEYNOTE-689 primary publication online now NEJM. It’s been an incredible journey with DAdkins Siteman Cancer Center @WUSM. All started in early 2010s / now with U.S. FDA approval and a new standard of care! Dana-Farber News Brigham and Women's Hospital Brigham and Women’s Department of Surgery

New standard of care for HPV- HNSCC!! All started at WashU 10 years ago - very proud to be a part and to see this play out to such an amazing outcome. Congrats Doug and Ravi Uppaluri, MDPhD !

The U.S. FDA has approved perioperative pembrolizumab adjuvant radiotherapy for adult patients with HNSCC with 🔹resectable, locally advanced disease 🔹who express PD-L1 with a CPS of at least 1, per an FDA-approved test. 🔗 onclive.com/view/fda-appro… #hnscc #oncology